Welcome to the Discoveries from AHA: PCI-STEMI Resource Center. This resource center provides take-home messages from the 2016 American Heart Association Scientific Sessions on topics related to recent advances in PCI-STEMI via coverage of sessions on treatment options – including bivalirudin, prasugrel and tirofiban – and interviews with leading clinicians. Bookmark this page and visit often to hear experts provide context on the major findings presented on updates in percutaneous coronary intervention, including results of the PIONEER AF-PCI trial, which demonstrated rivaroxaban conferred less bleeding risk than warfarin in patients with atrial fibrillation undergoing PCI with stenting. In addition, view new analyses of the TAO trial, which has previously demonstrated that otamixaban did not reduce ischemic events, but did increase bleeding in patients with non-ST-elevation ACS, and the ARISTOTLE trial, which has demonstrated that major bleeding was associated with increased risk for death, ischemic stroke and MI, and the risk was similarly elevated regardless of treatment with warfarin or apixaban.
Meeting News
February 1, 2017
NEW ORLEANS — The use of PCI to treat patients with acute myocardial infarction and cardiogenic shock is associated with high procedural…
Meeting News
January 31, 2017
NEW ORLEANS — Although patients who underwent a second CABG had an increased 30-day mortality compared with individuals who underwent PCI…
Meeting NewsVideo
January 27, 2017
NEW ORLEANS — There are multiple ongoing clinical trials that could potentially influence the way cardiologists treat patients with atrial…
Meeting News
January 26, 2017
NEW ORLEANS — Patients who underwent PCI for chronic total occlusion experienced similar technical and procedural success rates regardless of…
Meeting News
January 11, 2017
NEW ORLEANS — Patients who presented to the hospital after experiencing an out-of-hospital cardiac arrest and who then underwent coronary…
Meeting NewsVideo
January 10, 2017
NEW ORLEANS — Emmanouil S. Brilakis, MD, PhD, director of the center for advanced coronary interventions at the Minneapolis Heart Institute…
Meeting News
January 9, 2017
NEW ORLEANS — Patients with high-risk non-STEMI undergoing coronary angiography within 12 hours of their first electrocardiogram demonstrated…
Meeting News
January 8, 2017
NEW ORLEANS — Individuals with diabetes who underwent dual antiplatelet therapy for 1 year after undergoing percutaneous coronary intervention…
Meeting NewsVideo
December 22, 2016
NEW ORLEANS – In this video, Joseph B. Muhlestein, MD, co-director of cardiology research at Intermountain Medical Center in Murray, Utah…
Meeting News
December 21, 2016
Extended treatment with dual antiplatelet therapy reduced the risk of ischemic events and bleeding after PCI in patients with and without peripheral…